111 related articles for article (PubMed ID: 2092151)
1. Breast cancer mucin antigen (BCM) determination by IMX: a preliminary study of epidemiological distribution of the serum levels in gynecological diseases.
Torre GC; Barbetti V; Lanfranco E; Robutti M; Foglia M; Corongiu F; Vigliercio GP
J Nucl Med Allied Sci; 1990; 34(4 Suppl):59-62. PubMed ID: 2092151
[No Abstract] [Full Text] [Related]
2. A multicentre evaluation of tumour marker determinations using the automatic Enzymun-Test Systems ES 300 and ES 600/700.
van Dalen A; Kessler AC
Eur J Clin Chem Clin Biochem; 1996 Apr; 34(4):377-84. PubMed ID: 8704058
[TBL] [Abstract][Full Text] [Related]
3. Preoperative determination of CASA (Cancer Associated Serum Antigen) and CA-125 for the discrimination between benign and malignant pelvic tumor mass: a prospective study.
Sehouli J; Akdogan Z; Heinze T; Könsgen D; Stengel D; Mustea A; Lichtenegger W
Anticancer Res; 2003; 23(2A):1115-8. PubMed ID: 12820357
[TBL] [Abstract][Full Text] [Related]
4. [Preliminary experience with BCM-IMx as a pretreatment marker of breast tumors].
Fernández Llana B; Fernández Fernández M; Suárez B; Allende MT
Rev Clin Esp; 1992 Mar; 190(4):209. PubMed ID: 1589619
[No Abstract] [Full Text] [Related]
5. Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma.
Hasholzner U; Baumgartner L; Stieber P; Meier W; Hofmann K; Fateh-Moghadam A
Anticancer Res; 1994; 14(6B):2743-6. PubMed ID: 7532929
[TBL] [Abstract][Full Text] [Related]
6. Clinical value of squamous cell carcinoma antigen (SCC-A) in Egyptian gynecologic cancer patients.
Salman T; el-Ahmady O; Tony O; Darwish M
Anticancer Res; 1997; 17(4B):3083-6. PubMed ID: 9329607
[TBL] [Abstract][Full Text] [Related]
7. [Experiences with the cancer marker CA 125 in gynecologic diseases].
Pilgrim G; von Broen B; Johannsmeyer KD
Z Gesamte Inn Med; 1989 Apr; 44(8):251-4. PubMed ID: 2741520
[TBL] [Abstract][Full Text] [Related]
8. [Tumor markers in the diagnosis and prognosis of breast cancer].
Seliuzhitskiĭ IV; Skvortsov SV; Lytsar BN; Khomenko LP
Klin Med (Mosk); 1993; 71(2):25-7. PubMed ID: 8046917
[TBL] [Abstract][Full Text] [Related]
9. [Pre- and post-therapeutic serum concentrations of mucin-like carcinoma-associated antigen in patients with breast cancer].
Fuith LC; Artner-Dworzak E; Schröcksnadel H; Müller-Holzner E; Daxenbichler G; Heim K
Gynakol Rundsch; 1989; 29 Suppl 2():397-9. PubMed ID: 2613061
[No Abstract] [Full Text] [Related]
10. MCA performance in preoperative breast cancer patients.
Donadeo A; Micelli G; Quaranta M; Atlante A; Schittulli F
Anticancer Res; 1995; 15(2):527-9. PubMed ID: 7763034
[TBL] [Abstract][Full Text] [Related]
11. The use of mucin-specific monoclonal antibodies and lectins in the detection of tumor-associated serum markers in gynecological cancer.
Devine PL; McGuckin MA; Ramm LE; Harada H; Ward BG
Cancer Biochem Biophys; 1993 Sep; 13(4):221-38. PubMed ID: 8521372
[TBL] [Abstract][Full Text] [Related]
12. Mammary serum antigen (MSA), Ca 549, CA 15-3 and CEA in breast cancer preoperative sensitivity and correlation to prognostic factors.
Heinze T; Schürenkämper P; Minguillon C; Lichtenegger W
Anticancer Res; 1997; 17(4B):2953-4. PubMed ID: 9329573
[TBL] [Abstract][Full Text] [Related]
13. [Serum BCM in patients with nontumorous diseases. Preliminary results].
Allende MT; Vizoso F; Sampedro A; Ruibal A
Rev Clin Esp; 1990 Oct; 187(5):254-5. PubMed ID: 2102542
[No Abstract] [Full Text] [Related]
14. Clinical value of a new tumor marker (M.C.A.) in the breast cancer follow-up.
Cappellari A; Bagarella M; Corradi G
Boll Ist Sieroter Milan; 1990; 69(1):315-8. PubMed ID: 2102115
[TBL] [Abstract][Full Text] [Related]
15. [CA50].
Kawabe T
Nihon Rinsho; 2005 Aug; 63 Suppl 8():645-6. PubMed ID: 16149601
[No Abstract] [Full Text] [Related]
16. Clinical use of gynaecologic tumour markers.
Halila H; Alfthan H; Stenman UH
Ann Chir Gynaecol; 1989; 78(1):65-70. PubMed ID: 2547331
[TBL] [Abstract][Full Text] [Related]
17. A comparative study of four serological tumor markers for the detection of breast cancer.
Clinton SR; Beason KL; Bryant S; Johnson JT; Jackson M; Wilson C; Holifield K; Vincent C; Hall M
Biomed Sci Instrum; 2003; 39():408-14. PubMed ID: 12724928
[TBL] [Abstract][Full Text] [Related]
18. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E
Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729
[TBL] [Abstract][Full Text] [Related]
19. Serum CYFRA 21-1 is one of the most reliable tumor markers for breast carcinoma.
Rodríguez CA; Cruz JJ; Martín T; Gómez A; Olaverri A; Hernández M
Cancer; 2002 Aug; 95(3):670-1; author reply 671. PubMed ID: 12209762
[No Abstract] [Full Text] [Related]
20. Evaluation of MCA and CA 15-3 in tissue and in serum of patients with breast carcinoma: preliminary results.
Reale G; Giovagnoli MR; Vecchione A; Cosentino L; Benci F; Manna A; Marchei G; Vittori I; Frati L
J Nucl Med Allied Sci; 1990; 34(4 Suppl):53. PubMed ID: 2092150
[No Abstract] [Full Text] [Related]
[Next] [New Search]
